Omega-3 Salt and Boswellia Composition for SPM Bioavailability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for delivering omega-3 fatty acids and Boswellia extracts fail to effectively stimulate the production of specialized pro-resolving lipid mediators (SPMs) in humans, leading to limited bioavailability and ineffective treatment of inflammatory conditions.

Innovation Solution

A combination of omega-3 fatty acid salts, such as EPA and DHA, with extracts of Boswellia species, particularly boswellic acids, is used to synergistically enhance the production of SPMs, utilizing formulations like nanocellulose carriers and enteric coatings for targeted release in the gastrointestinal tract.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If omega-3 fatty acids are administered in the fasted state or as supplements, then they can be consumed independently from meals, but bioavailability is reduced due to lack of digestive fluid secretion

Engineering Contradiction:
Improveindependent consumptionVSAvoidbioavailability
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent applies preliminary action by pre-formulating omega-3 fatty acids in salt forms (ammonium, potassium, sodium, calcium, magnesium, or zinc salts) that are designed to be readily soluble and bioavailable without requiring meal-associated digestive enzymes. This preliminary chemical modification enables the fatty acids to be effectively absorbed even when consumed in the fasted state, eliminating the dependency on meal-triggered digestive fluid secretion while maintaining high bioavailability

Inventive Principle:
Principle #10Preliminary action

2Manufacturing precision

If advanced formulation technologies with release polymers are used to target the lower digestive system, then omega-3 fatty acids can be released in the small or large intestine, but natural solubilization mechanisms are less effective reducing bioavailability

Engineering Contradiction:
Improvetargeted releaseVSAvoidbioavailability
Core Design Contradiction:
Manufacturing precisionVSReliability

Solution Approach 1:

The patent applies parameter changes by transforming omega-3 fatty acids into salt forms with fundamentally different solubility and dissolution characteristics. These salt forms are designed to dissolve and release omega-3 fatty acids across the entire gastrointestinal tract including the stomach and upper intestine, rather than being restricted to lower intestinal release. This parameter change in chemical form enables effective solubilization and absorption throughout the digestive system, maintaining high bioavailability while providing flexibility in release timing and location

Inventive Principle:
Principle #35Parameter changes

3Ease of manufacture

If hydrophobic nutrients are provided in capsule or pill form, then they can be consumed as supplements, but solubilization and bioavailability are low

Engineering Contradiction:
Improvesupplement formulationVSAvoidsolubilization
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent applies parameter changes by converting hydrophobic omega-3 fatty acids into hydrophilic salt forms through chemical modification. This fundamental parameter change in solubility characteristics enables the fatty acids to dissolve readily in aqueous environments throughout the digestive tract, eliminating the solubilization problems associated with traditional hydrophobic formulations while maintaining the convenient capsule or pill supplement format

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent applies composite materials by creating salt compounds that combine omega-3 fatty acids with various cations (ammonium, potassium, sodium, calcium, magnesium, or zinc). These composite salt forms integrate the beneficial properties of both the omega-3 fatty acid (anti-inflammatory, cardio- and neuroprotective effects) and the metal cation, while achieving superior solubility and bioavailability compared to the parent fatty acid alone

Inventive Principle:
Principle #40Composite materials

Data Source

PatentEP4007500B1Preparation comprising omega-3 fatty acid salts and extracts of gum resins from boswellia species
Publication Date: 2026.03.25 EVONIK OPERATIONS GMBH
  • EP4007500B1 patent drawingFigure 1
  • EP4007500B1 patent drawingFigure 2
  • EP4007500B1 patent drawingFigure 3

AI summary

The invention relates to preparations comprising at least one extract of gum resins from Boswellia species and at least one omega-3 fatty acid salt selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Surprisingly, these combinations of extracts of gum resins from Boswellia species and polyunsaturated fatty acid salt cause a marked and unexpected increase in the biosynthesis of specialized pro-resolving mediators (SPM) in a synergistic manner, proposing benefit for resolution of inflammatory conditions.